This is plausible according to CANTOS results, since canakinumab effects in decreasing lung cancer incidence and mortality were double in current than in past smokers overall, and quadruple when the high-dose group was examined alone, with current smokers having higher KRAS mutation rates than never-smokers [4,25,26,27]. This evidence concerns the gene KRAS and lung carcinoma.